181 related articles for article (PubMed ID: 36170500)
21. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
[TBL] [Abstract][Full Text] [Related]
22. Continuous glucose monitoring and intensive treatment of type 1 diabetes.
; Tamborlane WV; Beck RW; Bode BW; Buckingham B; Chase HP; Clemons R; Fiallo-Scharer R; Fox LA; Gilliam LK; Hirsch IB; Huang ES; Kollman C; Kowalski AJ; Laffel L; Lawrence JM; Lee J; Mauras N; O'Grady M; Ruedy KJ; Tansey M; Tsalikian E; Weinzimer S; Wilson DM; Wolpert H; Wysocki T; Xing D
N Engl J Med; 2008 Oct; 359(14):1464-76. PubMed ID: 18779236
[TBL] [Abstract][Full Text] [Related]
23. Home Use of an Artificial Beta Cell in Type 1 Diabetes.
Thabit H; Tauschmann M; Allen JM; Leelarathna L; Hartnell S; Wilinska ME; Acerini CL; Dellweg S; Benesch C; Heinemann L; Mader JK; Holzer M; Kojzar H; Exall J; Yong J; Pichierri J; Barnard KD; Kollman C; Cheng P; Hindmarsh PC; Campbell FM; Arnolds S; Pieber TR; Evans ML; Dunger DB; Hovorka R
N Engl J Med; 2015 Nov; 373(22):2129-2140. PubMed ID: 26379095
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
26. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
[TBL] [Abstract][Full Text] [Related]
27. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
[TBL] [Abstract][Full Text] [Related]
28. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
[TBL] [Abstract][Full Text] [Related]
29. Utility and Safety of Backup Insulin Regimens Generated by the Bionic Pancreas: A Randomized Study.
Mauras N; Damiano ER; El-Khatib FH; Marak MC; Calhoun P; Ruedy KJ; Balliro C; Li Z; Beck RW; Russell SJ
Diabetes Technol Ther; 2023 Jun; 25(6):437-441. PubMed ID: 36877259
[TBL] [Abstract][Full Text] [Related]
30. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial.
Pratley RE; Kanapka LG; Rickels MR; Ahmann A; Aleppo G; Beck R; Bhargava A; Bode BW; Carlson A; Chaytor NS; Fox DS; Goland R; Hirsch IB; Kruger D; Kudva YC; Levy C; McGill JB; Peters A; Philipson L; Philis-Tsimikas A; Pop-Busui R; Shah VN; Thompson M; Vendrame F; Verdejo A; Weinstock RS; Young L; Miller KM;
JAMA; 2020 Jun; 323(23):2397-2406. PubMed ID: 32543682
[TBL] [Abstract][Full Text] [Related]
31. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
[TBL] [Abstract][Full Text] [Related]
33. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
[TBL] [Abstract][Full Text] [Related]
34. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial.
Laffel LM; Kanapka LG; Beck RW; Bergamo K; Clements MA; Criego A; DeSalvo DJ; Goland R; Hood K; Liljenquist D; Messer LH; Monzavi R; Mouse TJ; Prahalad P; Sherr J; Simmons JH; Wadwa RP; Weinstock RS; Willi SM; Miller KM; ;
JAMA; 2020 Jun; 323(23):2388-2396. PubMed ID: 32543683
[TBL] [Abstract][Full Text] [Related]
35. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
36. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
[TBL] [Abstract][Full Text] [Related]
37. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
[TBL] [Abstract][Full Text] [Related]
38. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
[TBL] [Abstract][Full Text] [Related]
39. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
van Bon AC; Bode BW; Sert-Langeron C; DeVries JH; Charpentier G
Diabetes Technol Ther; 2011 Jun; 13(6):607-14. PubMed ID: 21457066
[TBL] [Abstract][Full Text] [Related]
40. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
